Literature DB >> 6971120

Increase in T gamma lymphocytes in B-cell chronic lymphocytic leukaemia. II. Correlation with clinical stage and findings in B-prolymphocytic leukaemia.

D Catovsky, F Lauria, E Matutes, R Foa, V Mantovani, S Tura, D A Galton.   

Abstract

The proportion of T gamma and T mu lymphocytes was studied in 40 cases of B-chronic lymphocytic leukaemia (B-CLL) and six of B-prolymphocytic leukaemia (B-PLL). The significant increase in T gamma cells, previously reported in two small B-CLL series, was confirmed and shown to be directly correlated with the clinical stages of the disease (P less than 0.01 to less than 0.001). The normal T mu:T gamma ratio (2.3:1) was reversed in B-CLL (1:1.4) and B-PLL (1:1.9). The proportion of T mu cells was decreased but was not related to stage. Our findings suggest that the increase in T gamma cells may be responsible for the hypogammaglobulinaemia of B-CLL. This is supported by two sets of observations. First, serum Ig levels were more often normal in cases in Stages 0 and I than in Stages II-IV (P less than 0.05), while the levels of two or three Ig classes were below normal in Stages II-IV twice as frequently. Secondly, splenic irradiation in one case was followed by a fall in the absolute number of T gamma lymphocytes, a reversion to normal of the T mu: T gamma ratio and an improvement in serum Ig levels. Thus, the imbalance in ;the regulatory T-cell subsets may provide an important clue to understand the pathogenic mechanism of the immunodeficiency in the chronic B-cell leukaemias.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6971120     DOI: 10.1111/j.1365-2141.1981.tb02682.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Cytotoxic lymphocytes in B-cell chronic lymphocytic leukemia. A flow cytometric study of peripheral blood, lymph nodes and bone marrow.

Authors:  L W Terstappen; B G de Grooth; I Segers-Nolten; J Greve
Journal:  Blut       Date:  1990-02

2.  Impaired mitogen responses of the non-leukaemic B cells from patients with chronic lymphocytic leukaemia.

Authors:  A Morgan; J Eaves; J W Mockford; V Malkovska
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

3.  Autoimmunity in chronic lymphocytic leukaemia.

Authors:  T J Hamblin; D G Oscier; B J Young
Journal:  J Clin Pathol       Date:  1986-07       Impact factor: 3.411

4.  Flow cytometric analysis of T-lymphocyte subpopulations in B-cell chronic lymphocytic leukemia: correlation with clinical stage.

Authors:  M L Hautekeete; R F De Bock; D R Van Bockstaele; G C Colpin; Z N Berneman; M E Peetermans
Journal:  Blut       Date:  1987-11

5.  Reduced T lymphocyte colonies in B chronic lymphocytic leukaemia. III. Evidence of a proliferative abnormality of the T helper cell population.

Authors:  R Foa; F Lauria
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

6.  Further evidence for T cell abnormalities in chronic lymphocytic leukaemia of the B cell type.

Authors:  F Herrmann; G Sieber; Z Chen; B Enders; B Komischke; H Rühl
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

7.  Cell-marker studies in CLL with monoclonal OKT antisera and lactic dehydrogenase isoenzyme analysis.

Authors:  L Sabbe; J Plum; M De Smedt; G Leroux; A Louwagie; A Criel
Journal:  Blut       Date:  1983-05

8.  T-cell imbalances in patients with multiple myeloma: an analysis by monoclonal antibodies.

Authors:  C D Platsoucas; H J Hansen; J R Redman; S Berenson; B J Lee; B D Clarkson
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

9.  T cell subpopulations in CLL: methods of T cell enrichment artificially alter proportions of OKT4 and OKT8 positive cells.

Authors:  A M Dickinson; S George; S J Proctor
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

10.  Autoimmunity in chronic lymphocytic leukaemia.

Authors:  M Lischner; M Prokocimer; A Zolberg; M Shaklai
Journal:  Postgrad Med J       Date:  1988-08       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.